Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
Completed
Human Genome Sciences Inc.
Phase 2
2003-10-01
The purpose of this study is to evaluate the safety and efficacy of 3 different doses of
belimumab, administered in addition to standard therapy, in patients with active SLE disease.
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
Completed
Human Genome Sciences Inc.
Phase 2
2003-12-01
The purpose of this study is to evaluate the safety and efficacy of 3 different doses of
belimumab, administered in addition to standard therapy, in patients with rheumatoid
arthritis (RA).
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
Completed
GlaxoSmithKline
Phase 3
2006-12-01
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on
quality of life of two different doses of belimumab administered in addition to standard
therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE)
disease.
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
Completed
Human Genome Sciences Inc.
Phase 3
2006-12-01
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on
quality of life of two different doses of belimumab administered in addition to standard
therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE)
disease.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.